icone plus
Contact Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité QALSODY (tofersen) dans l’indication « traitement des adultes atteints de sclérose latérale amyotrophique (SLA) associée à une mutation du gène superoxyde dismutase 1 (SOD1) ».
See also
HAS opinions and decisions
22/10/2024
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
yXnHFqwMQMEQp5Xy
Listen
